iRhythm (IRTC) 2025 Conference June 17, 2025 01:40 PM ET Speaker0 Thank you. Okay. We're gonna start the next this one? Gonna start the next thank you. Next fireside here with iRhythm. And we have Dan Wilson, CFO, and Stephanie Zitkiewicz. Sorry, Stephanie. I always always fumble over that. But thanks for joining us, both of you, and looking forward to a good discussion here. If anyone has questions throughout the course our fireside, please raise your hand and we'll try to try to get you to get you a mic. ...

Key Takeaways CNI will invest $85M in Michigan for railyard upgrades and expanded intermodal capacity in 2025. Last year, CNI spent $79M in Michigan to support infrastructure and track maintenance projects. CNI continues broad North American investment with recent expansions across the United States and Canada.Canadian National Railway Company (CNI) is forging ahead with a $85 million investment in Michigan, as part of its 2025 capital investment program, signaling strong confidence in the region’s econom ...

Self-driving cars are slowly becoming less sci-fi and more real-world as companies like Waymo, the driverless arm of Google's parent Alphabet, expand into more cities. On Tuesday, the robotaxi service stretched into more parts of the San Francisco Bay Area, and it'll also be extending its reach in Los Angeles this week.  Now, Bay Area riders can hail a fully autonomous Waymo ride in Brisbane, South San Francisco, San Bruno, Millbrae and Burlingame via the Waymo One app, and select riders can access Mountain ...

Walmart reportedly aims to enable consumers to make purchases through TV remotes and interfaces while they are watching TV shows.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.This plan is one of several that the ...

上海黄金交易所黄金T+D 6月17日（周二）晚盘收盘上涨0.05%报784.0元/克； 上海黄金交易所白银T+D 6月17日（周二）晚盘收盘上涨1.59%报8955.0元/千克。 黄金延期 白银延期 ...

机构：东北证券 研究员：杨占魁 2027 年实现营业收入4.24/6.76/10.81 亿元，对应PS 为52.83X/33.14X/20.72X，首次覆盖，给予"买入"评 级。 风险提示：技术迭代不及预期风险、技术创新与产品研发不足的风险、新客户及合作方开拓不及预期风 险、制药及材料行业变革的风险、业绩预测和估值判断不及预期的风险。 点评 2024 年营收突破商业化门槛，亏损持续收窄，现金流储备充足2024 年，公司实现营收2.66 亿元（同比 +52.8%），主要系智能机器人解决方案收入同比增长87.8%和药物发现解决方案收入同比增长18.2%。 同时，公司已提前达成联交所对已商业化公司的收入门槛要求（2.5 亿港元），标志着在公司步入商业 化发展的新阶段。2024 年，公司实现经调整净亏损4.57 亿元（同比收窄12.5%），未来随着公司营收规 模持续增长，公司有望实现扭亏为盈；截至2024 年12 月31 日，公司现金储备达31.23亿元，如计入2025 年Q1 的两次配售募集所得款项净额29.68 亿元，预计可支持未来10 年运营，为研发投入和业务拓展提 供坚实保障。 AI+机器人赋能生命科学，合作 ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

All resolutions recommended by the Board of Directors approved (quorum: 27.21%). Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 17, 2025. The quorum on first convening amounted to 27.21% and shareholders approved all ...

6月12日，CDE官网显示，山东诺禾康药业有限公司提交的4类仿制化药乌帕替尼缓释片上市申请已获受理。 乌帕替尼是由艾伯维（AbbVie）公司自主研发的新一代选择性和可逆性JAK1抑制剂。乌帕替尼口服缓释片于2019年8月16日获FDA批准上市，商品名为 RINVOQ，同年12月，在欧盟获EMA批准上市。 乌帕替尼缓释片自2019年上市以来销售额呈现爆发性增长。从上市初期的0.47亿美元迅速攀升至2020年的7.31亿美元，并在2021年突破16亿美元大关。2022 年销售额达到25.22亿美元。2023年，乌帕替尼在全球的销售额已达到约27亿美元。 根据IQVIA和EvaluatePharma的报告，乌帕替尼的全球市场需求在快速增长。预计到2026年，乌帕替尼的年销售额将接近80亿美元。 作为目前全球医学界最有前景的靶点之一，据摩熵医药数据库显示，JAK抑制剂在全国医院（全终端）累计销售额达24.9亿元，市场规模迅速攀升，由2019 年的0.56亿元增长至2023年的8.5亿元，复合年增长率达97.28%。乌帕替尼缓释片是其中的TOP3产品。 | 受理品种目录浏览 | 在审品种目录浏览 | | | | | | ...

中國人壽（02628.HK）作為港股市場中最具代表性的保險類藍籌股之一，近期技術走勢強勁，明顯走出低迷區間，逐步構建中期升勢格局。根據2025年6月 16日的交易資料，該股收報16.30港元，成交金額高達15.5億港元，是當日主板交投最活躍股份之一，亦反映資金在金融保險板塊中再度加倉的現象日益明 顯。 截止今日（17日）股價報18.58元，升幅0.87%。 回顧6月10日中國人壽(02628)窩輪表現，在正股大漲5.52%的帶動下，相關衍生品展現出驚人的槓桿效應。摩通認購證15771兩日內飆升37%，瑞銀認購證 15949上漲35%；牛證方面，法興牛證53998暴漲33%，摩通牛證53835上漲30%，充分展現了保險股行情啟動時的槓桿放大效應。 從技術形態來看，中國人壽股價已突破此前的關鍵阻力區16.00至16.14港元，並於過去幾個交易日穩步向上推進，目前接近17.10港元的短期壓力位。一旦能 穩固於此水準之上，將為挑戰前期高點19港元甚至20.50港元奠定基礎。整體技術走勢上，呈現典型的W底反彈結構，加上成交量配合理想，說明市場對此 次反彈有一定共識，不排除已步入新一輪中期升勢。 技術指標方面，MACD指 ...